Ribosomal Protein S6 Kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Ma, Qi ^a   Guin, Sunny ^b   Padhye, Snehal S ^b   Zhou, Yong Qing ^c   Zhang, Rui Wen ^b   Wang, Ming Hai ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 1; ENZYME INHIBITOR; MACROPHAGE ACTIVATING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE KINASE; RAS PROTEIN; RON RECEPTOR TYROSINE KINASE 1; RON RECEPTOR TYROSINE KINASE 2; S6 KINASE; SL 0101; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; MACROPHAGE STIMULATING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; RIBOSOMAL PROTEIN S6 KINASE, 90KDA, POLYPEPTIDE 3; RON PROTEIN; SCATTER FACTOR;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CELL NUCLEUS; CONTROLLED STUDY; DOG; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HUMAN; HUMAN CELL; KIDNEY CELL; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SPINDLE CELL; ANIMAL; CELL LINE; CELL MOTION; CELL STRAIN HT29; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN BINDING; PROTEIN TRANSPORT;

ANIMALS; CELL LINE; CELL MOVEMENT; CELL NUCLEUS; DOGS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE KNOCKDOWN TECHNIQUES; HEPATOCYTE GROWTH FACTOR; HT29 CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; RNA, SMALL INTERFERING; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79957485319     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-66     Document Type: Article

References (51)

1. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890. 10.1016/j.cell.2009.11.007, 19945376.
2. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119:1420-1428. 10.1172/JCI39104, 2689101, 19487818.
3. Kalluri EMTR. When epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009, 119:1417-1419. 10.1172/JCI39675, 2689122, 19487817.
4. Singh A, Settleman J. EMT, cancer-stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751. 10.1038/onc.2010.215, 20531305.
5. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006, 66:8319-8326. 10.1158/0008-5472.CAN-06-0410, 16951136.
6. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
7. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009, 9:265-273. 10.1038/nrc2620, 19262571.
8. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED. Mesenchymal-: role of fibroblast growth factor receptor-2. Cancer Res 2006, 66:11271-11278. 10.1158/0008-5472.CAN-06-2044, 17145872.
9. Ohashi S, Natsuizaka M, Wong GS, Michaylira CZ, Grugan KD, Stairs DB, Kalabis J, Vega ME, Kalman RA, Nakagawa M, Klein-Szanto AJ, Herlyn M, Diehl JA, Rustgi AK, Nakagawa H. Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res 2010, 70:4174-4184. 10.1158/0008-5472.CAN-09-4614, 3007622, 20424117.
10. Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT, Micklem DR, Akslen LA, Glackin C, Lorens JB. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA 2010, 107:1124-1129. 10.1073/pnas.0909333107, 2824310, 20080645.
11. Wendt MK, Smith JA, Schiemann WP. Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 2010, 29:6485-6498. 10.1038/onc.2010.377, 3076082, 20802523.
12. Yan C, Grimm WA, Garner WL, Qin L, Travis T, Tan N, Han YP. Epithelial to mesenchymal transition in human skin wound healing is induced by tumor necrosis factor-alpha through bone morphogenic protein-2. Am J Pathol 2010, 176:2247-258. 10.2353/ajpath.2010.090048, 2861090, 20304956.
13. Shin SY, Rath O, Zebisch A, Choo SM, Kolch W, Cho KH. Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition. Cancer Res 2010, 70:6715-6724. 10.1158/0008-5472.CAN-10-1377, 3012452, 20736375.
14. Martin JC, Herbert BS, Hocevar BA. Disabled-2 downregulation promotes epithelial-to-mesenchymal transition. Br J Cancer 2010, 103:1716-1723. 10.1038/sj.bjc.6605975, 21063401.
15. Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, Gouvin LM, Sharma VM, Mercurio AM. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 2010, 17:319-332. 10.1016/j.ccr.2010.02.030, 2881822, 20385358.
16. Vetter G, Saumet A, Moes M, Vallar L, Le Béchec A, Laurini C, Sabbah M, Arar K, Theillet C, Lecellier CH, Friederich E. miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers. Oncogene 2010, 29:4436-4448. 10.1038/onc.2010.181, 20543867.
17. Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J. ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell 2010, 38:114-127. 10.1016/j.molcel.2010.02.020, 2854677, 20385094.
18. Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia 2004, 6:603-610. 10.1593/neo.04241, 1531665, 15548370.
19. Zavadil J, Böttinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005, 24:5764-5774. 10.1038/sj.onc.1208927, 16123809.
20. Neth P, Ries C, Karow M, Egea V, Ilmer M, Jochum M. The Wnt signal transduction pathway in stem cells and cancer cells: influence on cellular invasion. Stem Cell Rev 2007, 3:18-29. 10.1007/s12015-007-0001-y, 17873378.
21. Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signaling. Nat Rev Mol Cell Biol 2008, 9:747-758. 10.1038/nrm2509, 18813292.
22. Doehn U, Hauge C, Frank SR, Jensen CJ, Duda K, Nielsen JV, Cohen MS, Johansen JV, Winther BR, Lund LR, Winther O, Taunton J, Hansen SH, Frödin M. RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. Mol Cell 2009, 35:511-522. 10.1016/j.molcel.2009.08.002, 19716794.
23. Smolen GA, Zhang J, Zubrowski MJ, Edelman EJ, Luo B, Yu M, Ng LW, Scherber CM, Schott BJ, Ramaswamy S, Irimia D, Root DE, Haber DA. A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration. Genes Dev 2010, 24:2654-2665. 10.1101/gad.1989110, 2994039, 21062900.
24. Roux PP, Richards SA, Blenis J. Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity. Mol Cell Biol 2003, 23:4796-4804. 10.1128/MCB.23.14.4796-4804.2003, 162206, 12832467.
25. Ghoda L, Lin X, Greene WC. The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaBalpha and stimulates its degradation in vitro. J Biol Chem 1997, 272:21281-21288. 10.1074/jbc.272.34.21281, 9261139.
26. Yoshimura T, Yuhki N, Wang MH, Skeel A, Leonard EJ. Cloning, sequencing, and expression of human macrophage stimulating protein (MSP, MST1) confirms MSP as a member of the family of kringle proteins and locates the MSP gene on chromosome 3. J Biol Chem 1993, 268:15461-15468.
27. Trusolino L, Comoglio PM. cell signalling fo r invasive growth. Nat Rev Cancer 2002, 2:289-300. 10.1038/nrc779, 12001990.
28. Wang MH, Zhou YQ, Chen YQ. Macrophage-stimulating protein and RON receptor tyrosine kinase: potential regulators of macrophage inflammatory activities. Scand J Immunol 2002, 56:545-553. 10.1046/j.1365-3083.2002.01177.x, 12472665.
29. Wang MH, Ronsin C, Gesnel MC, Coupey L, Skeel A, Leonard EJ, Breathnach R. Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science 1994, 266:117-119. 10.1126/science.7939629, 7939629.
30. Wang D, Shen Q, Chen YQ, Wang MH. Collaborative activities of macrophage-stimulating protein and transforming growth factor-beta1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase. Oncogene 2004, 23:1668-1680. 10.1038/sj.onc.1207282, 15001985.
31. Côté M, Miller AD, Liu SL. Human RON receptor tyrosine kinase induces complete epithelial-to-mesenchymal transition but causes cellular senescence. Biochem Biophys Res Commun 2007, 360:219-225. 10.1016/j.bbrc.2007.06.033, 17588532.
32. Yao HP, Luo YL, Feng L, Cheng LF, Lu Y, Li W, Wang MH. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Cancer Biol Ther 2006, 5:1179-1186. 10.4161/cbt.5.9.3073, 16880737.
33. Zhang Y, Kaplan-Lefko PJ, Rex K, Yang Y, Moriguchi J, Osgood T, Mattson B, Coxon A, Reese M, Kim TS, Lin J, Chen A, Burgess TL, Dussault I. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res 2008, 68:6680-6687. 10.1158/0008-5472.CAN-07-6782, 18701492.
34. Wang MH, Montero-Julian FA, Dauny I, Leonard EJ. Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein. Oncogene 1996, 13:2167-2175.
35. Xu XM, Zhou YQ, Wang MH. Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase. J Biol Chem 2005, 280:25087-25094. 10.1074/jbc.M414699200, 15878878.
36. Logan-Collins J, Thomas RM, Yu P, Jaquish D, Mose E, French R, Stuart W, McClaine R, Aronow B, Hoffman RM, Waltz SE, Lowy AM. Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res 2010, 70:1130-1140. 10.1158/0008-5472.CAN-09-0761, 2943733, 20103639.
37. Thobe MN, Gurusamy D, Pathrose P, Waltz SE. The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells. Oncogene 2010, 29:214-226. 10.1038/onc.2009.331, 2806938, 19838218.
38. Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res 2005, 65:1027-1034.
39. Richards SA, Dreisbach VC, Murphy LO, Blenis J. Characterization of regulatory events associated with membrane targeting of p90 ribosomal S6 kinase 1. Mol Cell Biol 2001, 21:7470-7480. 10.1128/MCB.21.21.7470-7480.2001, 99919, 11585927.
40. Zhang K, Yao HP, Wang MH. Activation of RON differentially regulates claudin expression and localization: role of claudin-1 in RON-mediated epithelial cell motility. Carcinogenesis 2008, 29:552-559.
41. Moreno-Bueno G, Portillo F, Cano A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 2008, 27:6958-6969. 10.1038/onc.2008.346, 19029937.
42. Wagh PK, Peace BE, Waltz SE. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 2008, 100:1-33.
43. Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ, Ellis LM. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. Cancer 2007, 109:1030-1039. 10.1002/cncr.22490, 17311308.
44. Valacca C, Bonomi S, Buratti E, Pedrotti S, Baralle FE, Sette C, Ghigna C, Biamonti G. Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. J Cell Biol 2010, 191:87-99. 10.1083/jcb.201001073, 2953442, 20876280.
45. Ma Q, Zhang K, Guin S, Zhou YQ, Wang MH. Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase. Mol Cancer 2010, 9:307-21. 10.1186/1476-4598-9-307, 3001714, 21114864.
46. Park JS, Park JH, Khoi PN, Joo YE, Jung YD. MSP-induced RON activation upregulates uPAR expression and cell invasiveness via MAPK, AP-1 and NF-{kappa}B signals in gastric cancer cells. Carcinogenesis 2011, 32:175-181. 10.1093/carcin/bgq241, 21081472.
47. Narasimhan M, Ammanamanchi S. Curcumin blocks RON tyrosine kinase-mediated invasion of breast carcinoma cells. Cancer Res 2008, 68:5185-5192. 10.1158/0008-5472.CAN-07-6883, 18593918.
48. Panta GR, Kaur S, Cavin LG, Cortés ML, Mercurio F, Lothstein L, Sweatman TW, Israel M, Arsura M. ATM and the catalytic subunit of DNA-dependent protein kinase activate NF-kappaB through a common MEK/extracellular signal-regulated kinase/p90(rsk) signaling pathway in response to distinct forms of DNA damage. Mol Cell Biol 2004, 24:1823-1835. 10.1128/MCB.24.5.1823-1835.2004, 350545, 14966265.
49. Torres MA, Eldar-Finkelman H, Krebs EG, Moon RT. Regulation of ribosomal S6 protein kinase-p90(rsk), glycogen synthase kinase 3, and beta-catenin in early Xenopus development. Mol Cell Biol 1999, 19:1427-1437. 116071, 9891076.
50. Pan ZZ, Devaux Y, Ray P. Ribosomal S6 kinase as a mediator of keratinocyte growth factor-induced activation of Akt in epithelial cells. Mol Biol Cell 2004, 15:3106-3113. 10.1091/mbc.E04-01-0043, 452568, 15107468.
51. Lu Y, Yao HP, Wang MH. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett 2007, 257:157-164. 10.1016/j.canlet.2007.08.007, 17889431.